Physician profile
Brandon E Cohen
NPI 1053775312
$11,156.45
in general payments reported to CMS, 2019-2025
31 companies · $4,339 in 2025
The $4,339 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $139 · 2021: $749 · 2022: $1,163 · 2023: $1,685 · 2024: $3,082 · 2025: $4,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,033 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,033.37 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,803.65 | 2020-2025 | Botox |
| Genzyme Corporation | $1,617.29 | 2021-2025 | |
| Janssen Biotech, INC. | $939.02 | 2020-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $927.82 | 2022-2025 | Dupixent |
| Ucb, INC. | $829.06 | 2024-2025 | Bimzelx |
| Incyte Corporation | $746.71 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $518.68 | 2021-2025 | Taltz, Ebglyss, Zepbound |
| Novartis Pharmaceuticals Corporation | $499.67 | 2024-2025 | |
| Amgen INC. | $397.88 | 2024-2025 | Otezla, Otezla |
| Pfizer INC. | $360.83 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $350.51 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $347.91 | 2021-2025 | Winlevi |
| Galderma Laboratories, L.P. | $301.79 | 2020-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $295.70 | 2021-2025 | Adbry, Anzupgo |
| Allergan, INC. | $222.51 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $135.68 | 2025 | Sofdra |
| Journey Medical Corporation | $123.20 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $121.19 | 2021 | |
| Dermavant Sciences, INC. | $98.54 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.48 | 2023-2024 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $76.18 | 2024 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $72.00 | 2024 | |
| Dermira, INC. | $64.19 | 2020-2021 | |
| Kyowa Kirin, INC. | $56.38 | 2022 | |
| Merz North America, INC. | $31.57 | 2021 | |
| Organon LLC | $29.80 | 2025 | Vtama |
| Surgenex LLC | $21.31 | 2025 | Renograft, Surgraft, Ardeograft |
| Almirall LLC | $20.00 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.08 | 2024 | Jublia, Cabtreo, Arazlo |
| Sebela Pharmaceuticals INC. | $17.57 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $17.25 | 2025 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.